Health Canada Approves Sevmia: First Generic Semaglutide for Weight Management
TL;DR: Health Canada approved Sevmia, Apotex's generic semaglutide, 29 Jun 2026 — first generic Wegovy for weight management.
What Did Health Canada Approve on 29 June 2026?
On 29 June 2026, Health Canada authorised Sevmia, a generic semaglutide injection developed by Toronto-based Apotex in partnership with Orbicular Pharmaceutical Technologies. The submission references Novo Nordisk's Wegovy as its brand comparator and was approved for the same indication: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and a BMI of 27 or higher.[1]
Apotex's press release, distributed via PR Newswire on 30 June, described Sevmia as the first generic semaglutide product Health Canada has authorised specifically against the weight-management indication.[2] Health Canada's own news release and coverage from the CBC and the Globe and Mail corroborated the approval date and the referenced Wegovy comparator.[3]
Approved is not the same as launched. Health Canada's authorisation confirms Sevmia met the bioequivalence and quality standard required to market a generic version of Wegovy. It does not, by itself, fix a shelf date, a price, or resolve any outstanding patent listings against the reference product — see the pricing section below.
Why Is Sevmia Called the "First" Generic When Two Others Already Existed?
Sevmia is technically the third generic semaglutide product Health Canada has approved, but the first cleared for the weight-management indication. The two earlier generic approvals referenced Novo Nordisk's Ozempic and were authorised only for type 2 diabetes — a narrower indication with a different regulatory dossier and a different patent-listing history than Wegovy's obesity/overweight and cardiovascular-risk-reduction claims.[3]
That distinction matters for researchers tracking the semaglutide literature because "generic semaglutide" headlines can obscure which indication, dose range, and injector device a given approval actually covers. Sevmia's authorisation is specific to the Wegovy-referenced weight-management and cardiovascular-risk profile; it says nothing new about the Ozempic-referenced diabetes generics that preceded it, and the three approvals are tracked separately in Health Canada's Notice of Compliance database.
What Does This Mean for Semaglutide Pricing and Access in Canada?
As of early July 2026, Apotex has not published a Sevmia list price or a confirmed shipping date, and pharmacy-tracking sites monitoring the launch report the same gap.[4] Health Canada's release notes that six further generic-semaglutide submissions from other manufacturers remain under review, with additional authorisation decisions expected "in the coming weeks and months."[1]
| Milestone | Date / status |
|---|---|
| Wegovy Health Canada authorisation (reference product) | 2021 |
| First two generic semaglutide approvals (Ozempic-referenced, diabetes only) | Prior to June 2026 |
| Sevmia approved (Wegovy-referenced, weight management) | 29 June 2026 |
| Six further generic submissions under review | Pending, as of 29 June 2026 |
| Sevmia retail price / launch date | Not published as of 4 July 2026 |
Generic pricing in Canada is regulated under the Patented Medicine Prices Review Board framework and typically settles well below brand pricing once two or more generics are actively dispensing in a given province, though the exact discount depends on how many competitors reach pharmacy shelves and how any patents still listed against Wegovy under the Patented Medicines (Notice of Compliance) Regulations are resolved. Reporting to date treats Sevmia's approval as a regulatory milestone rather than a confirmed near-term price change for patients.[4]
How Does This Compare to the US Generic-Tirzepatide Filing We Covered This Month?
We reported separately on Sandoz's US ANDA filing for generic tirzepatide, which the FDA accepted for review on the same date, 29 June 2026, but which cannot legally be approved before tirzepatide's US exclusivity expires in May 2027.[5] Sevmia is a step further along a comparable process: Health Canada has already granted full marketing authorisation, not merely accepted a filing for review, because Canada's generic drug framework and Wegovy's specific patent and data-protection timelines differ from the US Hatch-Waxman rules governing tirzepatide.
The two stories share a structural lesson for readers tracking GLP-1-class generics: an "approval" or "acceptance" headline describes a single national regulator's procedural step, not a global availability date. A Canadian approval has no bearing on US, UK, or EU generic timelines for the same molecule, and vice versa.
Does This Affect Research-Grade Semaglutide or Retatrutide Supply?
No. Sevmia is a licensed prescription medicine regulated by Health Canada for dispensing through the Canadian retail pharmacy system under a physician's prescription. It has no relationship to research-grade reagents supplied to laboratories for in vitro study.
1. Sevmia (this article)
A licensed generic pharmaceutical, bioequivalent to Wegovy, approved by Health Canada on 29 June 2026 for retail dispensing in Canada under prescription.
2. Branded semaglutide (Ozempic, Wegovy)
Novo Nordisk's original licensed products, approved separately by Health Canada, the FDA, and the MHRA. Neither this approval nor Sevmia changes their regulatory status.
3. Research-use reagents (what Velox Peptides supplies)
Velox Peptides does not stock semaglutide. Our retatrutide reference material — a related GLP-1/GIP/glucagon triple agonist — is manufactured and HPLC-verified strictly as an in vitro laboratory reagent for qualified researchers, and is not a medicine, has not been evaluated by Health Canada, the FDA, or the MHRA as a drug product, and carries no regulatory relationship to Sevmia or to Novo Nordisk's branded products.
What Should UK Researchers Take From This?
Health Canada's Notice of Compliance process is a Canada-specific mechanism under the Food and Drugs Act; it has no legal force in the UK and does not touch the Human Medicines Regulations 2012 or MHRA guidance governing research-reagent supply in Great Britain and Northern Ireland. A future UK generic-semaglutide approval, if and when the MHRA authorises one, would follow its own separate submission and patent-linkage process and carry its own separate timeline.
For researchers tracking the semaglutide and broader GLP-1 literature, the practical takeaway is that Sevmia's approval is a commercial and access milestone in one national market, not a new efficacy or safety data point, and it changes nothing about how semaglutide or retatrutide are supplied for laboratory research in the UK.
Velox Peptides does not sell semaglutide or Sevmia. Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Health Canada. Canada approves first generic semaglutide for weight loss. News release, 29 June 2026. canada.ca
- Apotex Inc. Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management. Press release, 30 June 2026. prnewswire.com
- CBC News. 1st generic semaglutide injection for weight loss approved: Health Canada. 2026. cbc.ca; corroborated by The Globe and Mail, theglobeandmail.com
- GLP1Prices.ca. Health Canada Approves Sevmia (Apotex): Canada's First Generic Wegovy. 2026. glp1prices.ca
- Sandoz. US FDA accepts Sandoz applications for proposed in-house development of generic tirzepatide GLP-1s. Press release, 29 June 2026. See our related guide: Sandoz Files for Generic Tirzepatide
Frequently Asked Questions
What did Health Canada approve on 29 June 2026?
Health Canada approved Sevmia, a generic semaglutide injection made by Apotex and developed with Orbicular Pharmaceutical Technologies, referencing Novo Nordisk's Wegovy. It is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, and to reduce the risk of non-fatal heart attack in adults with established cardiovascular disease and a BMI of 27 or higher.
Is Sevmia the first generic semaglutide in Canada?
No. It is the third generic semaglutide product Health Canada has authorised, but the first approved specifically for the weight-management indication — the two earlier generics referenced Ozempic and were approved only for type 2 diabetes.
Is Sevmia available to buy yet?
Approval is not the same as market launch. As of early July 2026, no Sevmia price or shipping date has been published, and generic launches in Canada typically depend on how any patents listed against Wegovy under the Patented Medicines (Notice of Compliance) Regulations are resolved.
Does this affect research-grade semaglutide or retatrutide supply from Velox Peptides?
No. Sevmia is a licensed prescription medicine regulated by Health Canada for the Canadian retail pharmacy market. Velox Peptides does not sell semaglutide or Sevmia in any form. Retatrutide, the GLP-1/GIP/glucagon triple agonist we do supply, is manufactured and HPLC-verified strictly as an in vitro research reagent and has no regulatory relationship to this approval.
How does this compare to the US generic-tirzepatide story?
Differently, and further along. In the US, Sandoz's tirzepatide ANDA was only accepted for FDA review on 29 June 2026 and cannot be approved before tirzepatide's exclusivity expires in May 2027. Sevmia, by contrast, has already been fully approved by Health Canada under Canada's separate generic drug framework — though, as with the US filing, approval does not by itself confirm a launch date or price.